Objective: The aim of this study was to observe the influence of Danlou tablets on blood lipids

C-reactive protein(CRP)

nuclear factor-κB(NF-κB) in patients with athemsclerosis(AS)

and discuss the effect and mechanism involved in the process of anti-AS. Method: In this study

eighty-seven cases were divided into control group and Danlou group (treatment group) randomly

with control group treated with rosuvastatin merely

while treatment group by Danlou tablets and in the addition of rosuvastatin. After the treatment for 12 weeks

total cholesterol (TC)

triglyceride (TG)

high-density lipoprotein (HDL)

low density lipoprotein (LDL)

lipoprotein a (LPa)

apolipoprotein a (ApoA)

apolipoprotein B (ApoB) in plasma were detected by automatic biochemical analyzer;CRP

NF-κB in peripheral blood were detected by the way of latex-enhanced immunoturbidimetric test and ELISA;carotid artery intima-media thickness (IMT) was detected by Philips ie33 ultrasound machine and plaque score of the AS was collected. Result: After the treatment

the level of TC

TG

LDL-C

LPa

ApoB in blood decreased

HDL in plasma rised

with significant difference (P<0.05

P<0.01) before and after treatment. TC

LDL-C

ApoB in plasma of the treatment group dropped obliviously

and there was significant difference compared with control group (P<0.05).It can be induced that it was more effective to combine conventional treatment with Danlou tablets than conventional treatment alone. Expression of CRP

NF-κB in treatment group reduced significantly

and there was significant difference compared with control group(P<0.01). According to the carotid intima-media thickness and plaque score displayed

AS plaque in treatment group declined significantly with significant difference(P<0.05). Conclusion: DanLou tablets could regulate the blood lipid levels effectively

and intervene in the carotid plaque progression. And one of the mechanisms of anti-AS is to lower the levels of CRP

NF-κB and other inflammatory cytokine.